Rural and free-standing cancer hospitals will not get access to voluntary 340B pricing on Bristol Myers Squibb’s expensive myeloma drugs Revlimid, Pomalyst, and Thalomid under a policy change the company announced last month.

Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs

Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.

Earlier this month, BMS announced that hospitals would face significant restrictions on access to 340B discounts in the contract pharmacy setting. At the same time, BMS said it would let covered entities excluded from its limited distribution network for Revlimid, Pomalyst, and Thalomid begin to receive 340B pricing on the drugs.

Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer